Adrenocortical carcinoma (ACC) is an orphan malignancy that has attracted increasing
attention during the last decade. Here we provide an update on advances in the field since …

Adrenocortical carcinoma (ACC) is an aggressive cancer characterized by poor survival.
Apart from radical surgery, there is a limited range of therapeutic options and mitotane …

Adrenocortical carcinoma (ACC) is a rare and aggressive endocrine tumour deriving from
the adrenal cortex. A correct therapeutic strategy requires a multidisciplinary approach …

Adrenocortical carcinoma is a heterogeneous and aggressive cancer that originates from
steroidogenic cells within the adrenal cortex. In this study, we have assessed for the …

Mitotane is the only adrenolytic drug approved by the Food and Drug Administration for
treating adrenocortical carcinoma (ACC). This drug has cytotoxic effects on tumour tissues; it …

The adrenal glands are paired endocrine organs that produce steroid hormones and
catecholamines required for life. Adrenocortical carcinoma (ACC) is a rare and often fatal …

Adrenocortical carcinoma (ACC) has a poor prognosis, and no new drugs have been
identified in decades. The absence of drug development can partly be attributed to a lack of …

Objective Mitotane is an important cornerstone in the treatment of pediatric adrenal cortical
tumors (pACC), but experience with the drug in the pediatric age group is still limited and …

Background: Mitotane (1, 1-dichloro-2-[o-chlorophenyl]-2-[p-chlorophenyl] ethane), a
cytostatic drug used for the treatment of adrenocortical carcinomas, is effective by triggering …

Accepted: 23 June 2015/Published online: 14 July 2015© Italian Society of Endocrinology
(SIE) 2015 advanced ACC remains disappointing for limited efficacy and significant toxicity …